Advances in chemotherapy for HER2-negative metastatic breast cancer

被引:3
|
作者
Mukai, Hirofumi [1 ]
Ito, Mayuko [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
关键词
Breast cancer; chemotherapy; quality of life (QOL); survival;
D O I
10.21037/cco.2018.06.01
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic breast cancer cannot be curable, but significant improvement in overall survival has been observed with the appearance of new agents. The purpose of treatment is to prolong survival and to improve quality of life by reducing cancer-related symptoms. To achieve these goals, individualized approach is required. Chemotherapy is used for patients with hormone receptor negative breast cancer or hormone receptor positive patients who have cancer-related symptoms. The choice of regimen (single-agent or a combination), selection of a specific therapy and the duration of treatment depend on multiple factors, including the tumor burden, general health status, prior treatments and toxicities, and patient preferences.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
    Kuemmel, Sherko
    Jackisch, Christian
    Mueller, Volkmar
    Schneeweiss, Andreas
    Klawitter, Sandra
    Lux, Michael P.
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 5423 - 5431
  • [22] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 63 - 68
  • [23] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [24] Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
    Zhengwu Sun
    Xiaoyan Lan
    Shizhao Xu
    Shen Li
    Yalin Xi
    BMC Cancer, 20
  • [25] Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
    Sun, Zhengwu
    Lan, Xiaoyan
    Xu, Shizhao
    Li, Shen
    Xi, Yalin
    BMC CANCER, 2020, 20 (01)
  • [26] Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
    Montagna, Emilia
    Cancello, Giuseppe
    Bagnardi, Vincenzo
    Pastrello, Davide
    Dellapasqua, Silvia
    Perri, Gino
    Viale, Giuseppe
    Veronesi, Paolo
    Luini, Alberto
    Intra, Mattia
    Calleri, Angelica
    Rampinelli, Cristiano
    Goldhirsch, Aron
    Bertolini, Francesco
    Colleoni, Marco
    CLINICAL BREAST CANCER, 2012, 12 (03) : 207 - 214
  • [27] S-1 versus taxanes for HER2-negative metastatic breast cancer
    Martin, Miguel
    Lopez-Tarruella, Sara
    LANCET ONCOLOGY, 2016, 17 (01): : 11 - 12
  • [28] Effectiveness of platinum-based chemotherapy for hormone receptor-positive HER2-negative metastatic breast cancer
    Uratani, Lucas Fernando
    Bermejo, Francesco Sansone
    Hashizume, Pedro HenriqueShimiti
    Bonadio, Renata Colombo
    Testa, Laura
    CANCER RESEARCH, 2021, 81 (04)
  • [29] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257